ASH 2021 | Updates on targeted therapy in the treatment of myeloma
Lukas John
• 14 Dec 2021
Lukas John, MD, University Hospital Heidelberg, Heidelberg, Germany, shares his insights into recent advances in precision therapy in multiple myeloma, drawing focus on BRAF inhibitors and Akt inhibitors. Dr John explains why there are difficulties with successful targeted therapy in myeloma, including the ability of tumors to develop resistance, the genetic heterogeneity of this disease, and emphasizes the need for further research to improve personalized treatment options for patients with multiple myeloma. This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, GA, 2021.
